Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598528 | 0.92 | CSF1R (0.61) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20598518 | 0.86 | NPC1 (0.66) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20598498 | 0.85 | NPC1 (0.65) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30501343 | 0.84 | NPC1 (0.64) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20598450 | 0.84 | NPC1 (0.64) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20598829 | 0.84 | NPC1 (0.72) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20598222 | 0.82 | PIM1 (0.46) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20598842 | 0.82 | NPC1 (0.45) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30501423 | 0.82 | PIM1 (0.46) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20623367 | 0.81 | CYP1A2 (0.69) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032642-B | Kinase inhibitors and methods of making and using the same | 里格尔药品股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| CN-111032642-A | Kinase inhibitors and methods of making and using | 里格尔药品股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPC1 2113/4885RAB9A 3145/4885CYP1A2 4620/4885 |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPC1 2113/4885RAB9A 3145/4885CYP1A2 4620/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | NPC1 1531/4885RAB9A 3101/4885CYP1A2 4132/4885 |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPC1 2113/4885RAB9A 3145/4885CYP1A2 4620/4885 |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | NPC1 1370/4885RAB9A 2995/4885CYP1A2 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.